BCIQ Profiles

Company Profile Report

Xospata poised for EU approval under accelerated assessment

EMA's CHMP recommended approval of Xospata for acute myelogenous leukemia in its September roundup.

Under accelerated assessment, the agency backed Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503)

Read the full 267 word article

How to gain access

Continue reading with a
two-week free trial.